Here, the frequencies of KRAS, NRAS and TP53 mutations were increased in relapsed MM patients compared to initial manifestations suggesting an induction of mutations by the treatment itself or increased resistance of mutation harboring subclones against VTD (185). The gene discussed is NRAS; the disease is Miyoshi myopathy.